Science & Enterprise subscription

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Genome Editing Builds Viral Disease Resistance in Pigs

Veterinary researchers used Crispr-Cas9, an emerging genome editing technique, to produce pigs with cells resistant to a common viral disease affecting commercial herds. . . . → Read More: Genome Editing Builds Viral Disease Resistance in Pigs

Nuclear Cancer Therapy Company Launches, Raises $25M

A new company developing cancer therapies combining nuclear radiation and synthetic antibodies is starting up in Hamilton, Ontario. . . . → Read More: Nuclear Cancer Therapy Company Launches, Raises $25M

Patent Issued for Peptides in Diabetes Gene Therapy

A U.S. patent was issued today for synthetic peptides that support gene therapies developed to treat type 2 diabetes and heart failure. . . . → Read More: Patent Issued for Peptides in Diabetes Gene Therapy

Stem Cells Launched on Current SpaceX Flight

Yesterday’s SpaceX launch from NASA’s Kennedy Spaceflight Center includes a shipment of adult stem cells to test their growth and proliferation in weightless conditions. . . . → Read More: Stem Cells Launched on Current SpaceX Flight

Online Pharmacies Seen Fueling Antibiotic Overuse

A study of pharmacies selling drugs online shows many of these sites offer antibiotics to consumers in the U.K. without prescriptions, which would be illegal in retail drug stores. . . . → Read More: Online Pharmacies Seen Fueling Antibiotic Overuse

Patent Office Decides for Broad and Editas in Crispr Case

The U.S. Patent and Trademark Office decided that the gene editing processes developed by Broad Institute and licensed to Editas Medicine do not interfere with techniques for genome editing created by University of California at Berkeley. . . . → Read More: Patent Office Decides for Broad and Editas in Crispr Case

Tissue Regeneration Start-Up Gains $33M in Early Funds

A new enterprise founded by researchers at Stanford University aims to discover and develop drugs that repair and regenerate tissue from stem cells. . . . → Read More: Tissue Regeneration Start-Up Gains $33M in Early Funds

Biotech Group Withholds Support for Germline Trial Report

A biotechnology industry association in the U.S. says its members are not ready to support recommendations in a new report permitting future clinical studies of genome editing for inheritable disease-causing traits. . . . → Read More: Biotech Group Withholds Support for Germline Trial Report

Cancer Drug Shown to Improve Survival Time in Dogs

A drug to treat a deadly cancer in dogs was shown in a clinical trial to extend the survival time of canine patients by 6 months or more, with potential applications in humans. . . . → Read More: Cancer Drug Shown to Improve Survival Time in Dogs

Biotechs License Solid Tumor Therapy in $2.1B Deal

Biotechnology enterprise Immunomedics Inc. is licensing its enhanced antibody-based treatment for solid tumor cancers to Seattle Genetics, a developer of similar cancer drugs. . . . → Read More: Biotechs License Solid Tumor Therapy in $2.1B Deal